Association of Growth Differentiation Factor-15 with Coronary Atherosclerosis and Mortality in a Young, Multiethnic Population: Observations from the Dallas Heart Study

被引:137
|
作者
Rohatgi, Anand [1 ,3 ]
Patel, Parag [1 ,3 ]
Das, Sandeep R. [1 ,3 ]
Ayers, Colby R. [2 ,3 ]
Khera, Amit [1 ,3 ]
Martinez-Rumayor, Abelardo
Berry, Jarett D. [1 ,3 ]
McGuire, Darren K. [1 ,2 ,3 ]
de Lemos, James A. [1 ,3 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Div Cardiol, Dept Internal Med, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA
[3] Donald W Reynolds Cardiovasc Clin Res Ctr, Dallas, TX USA
关键词
MYOCARDIAL-INFARCTION; RISK STRATIFICATION; INHIBITORY CYTOKINE-1; GENERAL-POPULATION; BETA SUPERFAMILY; DISEASE; FAILURE; EVENTS; MARKER; ASSAY;
D O I
10.1373/clinchem.2011.171926
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BACKGROUND: Growth differentiation factor 15 (GDF-15) is produced by cardiomyocytes and atherosclerotic lesions under stress conditions. Although higher circulating GDF-15 concentrations are associated with mortality across a spectrum of cardiovascular conditions, the relationship of GDF-15 with atherosclerosis and mortality in the general population remains undefined. METHODS: We measured plasma GDF-15 in 3219 participants of the Dallas Heart Study, a population sample of adults ages 30-65 years (55% women, 49% black). GDF-15 was analyzed in prespecified categories (< 1200; 1200-1799; and >= 1800 ng/L) and continuously. End points included prevalent coronary artery calcium (CAC > 10 Agatston units), increased CAC (CAC >= 100 Agatston units) by electron beam computed tomography, and mortality through a median 7.3 years of follow-up (120 deaths, 48 cardiovascular deaths). RESULTS: Increasing GDF-15 associated with older age, black race, hypertension, diabetes, smoking, left ventricular (LV) mass/body surface area, and worse renal function (P < 0.0001 for each). In multivariable models adjusted for traditional risk factors, renal function, and LV mass/body surface area, GDF-15 > 1800 ng/L was associated with CAC > 10 (odds ratio 2.1; 95% CI 1.2-3.7; P = 0.01), CAC >= 100 (odds ratio 2.6; 95% CI 1.4-4.9; P = 0.002), all-cause mortality (hazard ratio 3.5; 95% CI 2.1-5.9, P < 0.0001), and cardiovascular mortality (hazard ratio 2.5; 95% CI 1.1-5.8, P = 0.03). Adding log GDF-15 to fully adjusted models modestly improved the c statistic (P = 0.025), the integrated discrimination index (0.028; P = 0.0001) and the category-less net reclassification index (0.42; P = 0.002). These findings remained significant with further adjustment for high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, and cardiac troponin T. CONCLUSIONS: GDF-15 is independently associated with subclinical coronary atherosclerosis and mortality, and its potential role for risk stratification in the general population merits further evaluation. (C) 2011 American Association for Clinical Chemistry
引用
收藏
页码:172 / 182
页数:11
相关论文
共 50 条
  • [21] Temporal Pattern of Growth Differentiation Factor-15 Protein After Acute Coronary Syndrome (From the BIOMArCS Study)
    Buljubasic, Nermina
    Vroegindewey, Maxime M.
    Oemrawsingh, Rohit M.
    Asselbergs, Folkert W.
    Cramer, Etienne
    Liem, Anho
    van der Harst, Pim
    Maas, Arthur
    Ronner, Eelko
    Schotborgh, Carl
    Wardeh, Alexander J.
    Akkerhuis, K. Martijn
    Boersma, Eric
    AMERICAN JOURNAL OF CARDIOLOGY, 2019, 124 (01): : 8 - 13
  • [22] Growth/differentiation factor-15 from biomarker to target in cancer
    Stanciu, A. E.
    Bolovan, L. M.
    Lazar, A. M.
    Mutuleanu, M. D.
    Stanciu, M. M.
    Zamfirescu, A.
    Gales, L. N.
    Gherghe, M.
    ANNALS OF ONCOLOGY, 2022, 33 (08) : S1395 - S1395
  • [23] Symmetrical Dimethylarginine Predicts Mortality in the General Population Observations From the Dallas Heart Study
    Gore, M. Odette
    Lueneburg, Nicole
    Schwedhelm, Edzard
    Ayers, Colby R.
    Anderssohn, Maike
    Khera, Amit
    Atzler, Dorothee
    de Lemos, James A.
    Grant, Peter J.
    McGuire, Darren K.
    Boeger, Rainer H.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2013, 33 (11) : 2682 - 2688
  • [24] Growth differentiation factor-15 as candidate predictor for mortality in adults with pulmonary hypertension
    Geenen, Laurie W.
    Baggen, Vivan J. M.
    Kauling, Robert M.
    Koudstaal, Thomas
    Boomars, Karin A.
    Boersma, Eric
    Roos-Hesselink, Jolien W.
    van den Bosch, Annemien E.
    HEART, 2020, 106 (06) : 467 - 473
  • [25] Growth Differentiation Factor-15 Is a Predictor of Mortality in Critically Ill Patients with Sepsis
    Buendgens, Lukas
    Yagmur, Eray
    Bruensing, Jan
    Herbers, Ulf
    Baeck, Christer
    Trautwein, Christian
    Koch, Alexander
    Tacke, Frank
    DISEASE MARKERS, 2017, 2017
  • [26] Association between eating speed and atherosclerosis in relation to growth differentiation factor-15 levels in older individuals in a cross-sectional study
    Shimizu, Yuji
    Kawashiri, Shin-Ya
    Noguchi, Yuko
    Sasaki, Nagisa
    Matsuyama, Mutsumi
    Nakamichi, Seiko
    Arima, Kazuhiko
    Nagata, Yasuhiro
    Maeda, Takahiro
    Hayashida, Naomi
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [27] Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program
    Ferreira, Joao Pedro
    Packer, Milton
    Butler, Javed
    Filippatos, Gerasimos
    Pocock, Stuart J.
    Januzzi, James L.
    Sattar, Naveed
    Maldonado, Sandra Gonzalez
    Panova-Noeva, Marina
    Sumin, Mikhail
    Masson, Serge
    Anker, Stefan D.
    Zannad, Faiez
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (01) : 155 - 164
  • [28] Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure
    Kempf, Tibor
    von Haehling, Stephan
    Peter, Timo
    Allhoff, Tim
    Cicoira, Mariantonietta
    Doehner, Wolfram
    Ponikowski, Piotr
    Filippatos, Gerasimos S.
    Rozentryt, Plotr
    Drexler, Helmut
    Anker, Stefan D.
    Wollert, Kai C.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (11) : 1054 - 1060
  • [29] The clinical impact of growth differentiation factor-15 in heart disease: A 2019 update
    Arkoumani, Maria
    Papadopoulou-Marketou, Nektaria
    Nicolaides, Nicolas C.
    Kanaka-Gantenbein, Christina
    Tentolouris, Nikolaos
    Papassotiriou, Ioannis
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2020, 57 (02) : 114 - 125
  • [30] Growth Differentiation Factor-15 and Clinical Outcomes in Patients With Chronic Heart Failure
    de Avila, Diane Xavier
    di Candia, Angelo Michele
    Moreira, Gustavo Rodolfo
    Scaramussa, Victoria Depes
    Lopes, Renato D.
    Villacorta, Humberto
    JOURNAL OF CARDIAC FAILURE, 2024, 30 (05) : 734 - 736